Lantern Pharma Inc. · NASDAQ:LTRN

Lantern Pharma — Q1 2022 Earnings Presentation

20 slides from Lantern Pharma's earnings presentation, May 3, 2022

  1. Slide 1: First Quarter 2022 Operating & Financial Results Conference Call

    First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3 rd , 2022 4:30 PM Eastern Time NASDAQ :LTRN

  2. Slide 2: Forward-looking statements

    First Quarter 2022 Earnings 7KLVSUHVHQWDWLRQFRQWDLQVIRUZDUG  ORRNLQJVWDWHPHQWVZLWKLQWKHPHDQLQJRI6HFWLRQ  $RIWKH6HFXULWLHV$FWRI  DVDPHQGHGDQG 6HFWLRQ  (RIWKH6HFXULWLHV([FKDQJH$FWRI  DVDPHQGHG7KHVHIRUZDUG  ORRNLQJVWDWHPHQWVLQFOXGHDPRQJRWKHUWKLQJV

  3. Slide 3: Contents and Speakers

    Contents 01 Introduction 02 Q1 2022 Highlights 03 Scientific Progress 04 Financial Highlights 05 Q&A Speakers Panna Sharma Chief Financial Officer ΖQYHVWRU5HODWLRQV Chief Executive Officer, President and Director David Margrave Nicole Leber Chief Scientific Officer Dr. Kishor Bhatia Host

  4. Slide 4: Lantern Pharma: Leveraging A.I. to reduce oncology drug development costs

    First Quarter 2022 Earnings  Lantern Pharma Leveraging A.I. to reduce oncology drug development costs and improve the likelihood of success Abundance of data Proprietary A.I. platform RADR ® Accelerated timeline and reduced cost

  5. Slide 5: Q1 2022 Highlights

    First Quarter 2022 Earnings Australia Operation • Actively conducting multiple studies in Australia under Lantern Australian subsidiary • Takes advantage of R&D tax incentive program 5#039;5 p  ([SDQVLRQ ‡ 5#039;5 p  KDVVXUSDVVHG  ELOOLRQGDWDSRLQWV ‡ 3XUVXLQJDGGLWLRQDOELRSKDUPDFROODERUDWLRQV Sh

  6. Slide 6: Harmonic Clinical Trial – Phase 2 Trial for LP-300

    First Quarter 2022 Earnings +DUPRQLF Ƞ  &OLQLFDO7ULDO Ȃ  3KDVH  7ULDOIRU/3    5 ‡ +DUPRQLF Ƞ  FOLQLFDOWULDOLVD3KDVH  PXOWL  FHQWHUVWXG\WR HYDOXDWH/DQWHUQ ȇ VLQYHVWLJDWLRQDOGUXJ/3   ‡  SDWLHQWWZR  DUPRSHQODEHO  UDQGRPL]HGWULDO ‡ UDQGRPL]DWLRQLQD 

  7. Slide 7: LP-184 IND-enabling studies

    First Quarter 2022 Earnings /3   Ζ1'HQDEOLQJVWXGLHV 6 Completed Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○

  8. Slide 8: In vitro efficacy of LP-184 in brain metastases

    First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) ,  • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasized

  9. Slide 9: Lantern established an Australian subsidiary

    First Quarter 2022 Earnings /DQWHUQHVWDEOLVKHGDQ$XVWUDOLDQVXEVLGLDU\ 8 Subsidiary will allow: o Lantern to take advantage of Australia’s R&D Tax Incentive program, which provides tax offsets for eligible R&D expenditures o Lantern to conduct preclinical and IND enabling studies, many of which ar

  10. Slide 10: RADR Surpassed Billion Datapoints

    First Quarter 2022 Earnings RADR ® Surpassed 20 Billion Datapoints 9 2019 2020 Apr. 2021 Dec. 2021 2022* Ēĕ 8 100M 275M 450M 1.1 B ĔĽĖſ 10.4 B 2XUJRDOLVWRH[SDQG 5#039;5WR  ELOOLRQGDWDSRLQWV  GXULQJ  1. Focus on automation of data acquisition 2. Improve data user interface to other anal

  11. Slide 11: LP-300 Mechanism of action

    First Quarter 2022 Earnings LP - 300 Mechanism of action 3URWHLQ'HJUDGDWLRQ Panel A : LP - 300 adduct at Cys 1235 Panel B : LP - 300 adduct at Cys 1156 Panel C : Molecular surface of ALK with the LP - 300 - derived adduct at Cys 1156 ( yellow highlight ) Panel D : Binding site of the LP - 300 - der

  12. Slide 12: LP-184 IND enabling studies

    First Quarter 2022 Earnings LP - 184 IND enabling studies 11 &RPSOHWHG Ongoing Expected 6WXG\7\SH Method Results Dog non - GLP tox study NOAEL 0.3mg/kg for repeat weekly dosing (days 1, 8 and 15) At NOAEL in dogs LP - 184 PK parameters measured on dosing days 1 and 15 showed ○ t1/2 = 40 - 50 min ○

  13. Slide 13: In vitro efficacy of LP-184 in brain metastases

    First Quarter 2022 Earnings In vitro efficacy of our drug candidate LP - 184 in brain metastases ( mets .) , 12 • LP - 184 has activity in the primary and secondary cancers AND crosses the BBB. • Efficacy of LP - 184 may extend beyond primary brain cancers to other solid tumors that have metastasize

  14. Slide 14: LP-184 shows sensitivity in NERD as well as HRD cancers

    First Quarter 2022 Earnings LP - 184 shows exquisite sensitivity in NERD as well as HRD cancers 13 LP - 184 in HRD cancers LP - 184 in NERD cancers • NERD tumors are nucleotide excision repair deficient tumors whose phenotype is a result of mutations in genes responsible for excision DNA repair - th

  15. Slide 15: Financial Update Q1 2022

    First Quarter 2022 Earnings Financial Update Q1 2022 14 2022 2021 Operating expenses : General and administrative 1,406,160 1,173,258 Research and development 2,660,237 1,279,037 Total operating expenses 4,066,397 2,452,295 Loss from operations  (2,452,295) Interest + Other income, net (55,

  16. Slide 16: LTRN Share Information

    First Quarter 2022 Earnings LTRN Share Information 15 March 31, 2022 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,830,947 Warrants 177,998 Options (Employees, Management and Directors) 890,826 Fully Diluted Shares Outstanding 11,899,771 Date Shares Repurchased Average Price Total Paid inc

  17. Slide 17: Maria Maccecchini, Ph.D. nominated for election to Lantern's Board

    First Quarter 2022 Earnings Maria Maccecchini , Ph.D. was nominated for election to Lantern’s Board of Directors 16 Maria L. Maccecchini , Ph.D. Founder, President, Chief Executive Officer, and director of Annovis Bio ( NYSE: ANVS ) New Director Nominee Dr. Maccecchini will be presented alongside a

  18. Slide 18: Upcoming Events

    First Quarter 2022 Earnings Upcoming Events 9th Drug Discovery Strategic Summit Speaker: Kishor Bhatia MAY 9 13 Strategic Investment Conference Speaker: Panna Sharma MedVentures Conference 2022 Speaker: Panna Sharma 19 Augmented intelligence in drug discovery Xchange east coast, Speaker: Panna Sharm

  19. Slide 19: Key Corporate Objectives and Milestones

    First Quarter 2022 Earnings Key Corporate Objectives and Milestones 18 Ɣ /DXQFKRI 7KH+DUPRQLF Ƞ  7ULDO   3K  FOLQLFDOWULDOIRU/3   LQ16&/& Ɣ $GYDQFH/3   FOLQLFDOGHYHORSPHQW Ɣ /DXQFK3K  FOLQLFDOWULDOIRU/3   LQ JHQRPLFDOO\  GHILQHG VROLGWXPRUV Ɣ 'HVLJQ3K

  20. Slide 20: IR Contact

    Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1 - 972 - 277 - 1136 www.lanternpharma.com @LanternPharma

Lantern Pharma — Q1 2022 Earnings Presentation on 6ix